Valuation: Hyundai Bioscience Co., Ltd.

Capitalization 528B 374M 355M 330M 294M 526M 31.69B 581M 4.09B 1.52B 13B 1.4B 1.37B 56.17B P/E ratio 2022
-68.2x
P/E ratio 2023 -71.5x
Enterprise value 522B 370M 351M 326M 291M 520M 31.31B 574M 4.04B 1.5B 12.84B 1.39B 1.36B 55.5B EV / Sales 2022
137x
EV / Sales 2023 109x
Free-Float
87.08%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 14 CI
Hyundai Bioscience USA Signs an MOU with the University of California San Diego to Conduct an Investigator-Initiated Trial to Evaluate the Efficacy of Xafty Sep. 17 CI
Hyundai Bioscience Co., Ltd. to Conduct Phase 3 Clinical Trial for High-Risk Group of COVID-19 Patients with the Goal of Emergency Use Authorization Aug. 28 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 Aug. 14 CI
Hyundai Bioscience Co., Ltd. announced that it has received KRW 3 billion in funding Jun. 18 CI
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 3 billion in funding Jun. 16 CI
Hyundai Bioscience Co., Ltd., CnPharm Co., Ltd. and Yeonjin Kim completed the acquisition of 34.91% stake in ADM Korea Inc. from Mobiis Co., Ltd.. May. 19 CI
Hyundai Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 May. 16 CI
Hyundai Bioscience Co., Ltd. announced that it expects to receive KRW 18 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank May. 15 CI
Hyundai Bioscience's Antiviral for Dengue Fever to Enter Clinical Trials in Brazil Apr. 25 CI
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-Based Metabolic Anticancer Drug Targeting P53 Mutation Cancer Apr. 25 CI
Hyundai Bioscience Announces Its Successful Result from A Preclinical Study of A Niclosamide-Based Oral Anticancer Drug to Treat Triple-Negative Breast Cancer Apr. 22 CI
Hyundai Bioscience to Carry Out Global Clinical Tests Aimed At Treating All Serotypes of Dengue Virus Infection Apr. 19 CI
More news
1 day-3.49%
1 week-9.54%
Current month-6.68%
1 month-24.69%
3 months-31.10%
6 months-32.88%
Current year-49.16%
More quotes
1 week
13 100.00
Extreme 13100
14 610.00
1 month
13 100.00
Extreme 13100
17 710.00
Current year
13 100.00
Extreme 13100
26 350.00
1 year
13 100.00
Extreme 13100
30 350.00
3 years
13 100.00
Extreme 13100
41 600.00
5 years
6 310.00
Extreme 6310
66 300.00
10 years
2 825.00
Extreme 2825
66 300.00
More quotes
Director TitleAgeSince
Chief Executive Officer 65 2013-03-28
Corporate Officer/Principal 44 -
Corporate Officer/Principal 58 -
Manager TitleAgeSince
Director/Board Member 65 2013-03-28
Director/Board Member 66 -
Director/Board Member 62 -
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-3.49%-9.54%-54.24%-58.72%374M
-0.18%-2.37%+15.16%+16.83%412B
-0.07%-1.34%+22.74%+18.83%147B
+0.21%-2.02%+20.04%+23.50%77.46B
+1.13%+1.17%-2.75%+8.02%68.36B
-1.36%-4.02%+12.32% - 44.4B
-0.39%-0.85%-6.75%+36.17%28.95B
+2.34%+7.21%-42.94%-76.35%28.46B
+0.30%+0.76%+17.04%+5.62%19.42B
+1.32%-0.52%+19.00%+40.38%14.84B
Average +0.02%-1.63%-0.04%+1.59% 84.16B
Weighted average by Cap. +0.17%-1.73%+12.69%+14.60%
See all sector performances

Financials

2022 2023
Net sales 7.85B 5.56M 5.28M 4.91M 4.37M 7.82M 471M 8.64M 60.75M 22.58M 193M 20.87M 20.42M 835M 9.48B 6.71M 6.37M 5.93M 5.28M 9.45M 569M 10.43M 73.36M 27.26M 233M 25.21M 24.66M 1.01B
Net income -15.81B -11.19M -10.63M -9.88M -8.8M -15.75M -948M -17.38M -122M -45.45M -389M -42.03M -41.1M -1.68B -14.5B -10.26M -9.75M -9.07M -8.07M -14.44M -870M -15.95M -112M -41.69M -357M -38.55M -37.7M -1.54B
Net Debt -12.48B -8.84M -8.39M -7.81M -6.95M -12.44M -749M -13.73M -96.59M -35.9M -307M -33.19M -32.46M -1.33B -6.27B -4.44M -4.21M -3.92M -3.49M -6.24M -376M -6.89M -48.48M -18.02M -154M -16.66M -16.29M -666M
More financial data * Estimated data
Logo Hyundai Bioscience Co., Ltd.
HYUNDAI BIOSCIENCE CO., LTD. it is a Korea-based company mainly engaged in the manufacturing and sale of bio cosmetics and hair tonic products. It develops functional daily necessities such as shampoos, mask packs, creams, and tumor-targeted drug. The Company also sells liquid crystal display (LCD) monitors and digital signage display products. The Company distributes its products in domestic market, as well as to the overseas markets, including Europe, America and Japan.
Employees
54
More about the company
Date Price Change Volume
24-12-04 13,270.00 -3.49% 250,627
24-12-03 13,750.00 -0.36% 160,580
24-12-02 13,800.00 -2.95% 162,938
24-11-29 14,220.00 -2.34% 99,427
24-11-28 14,560.00 -0.75% 85,904

End-of-day quote Korea S.E., December 03, 2024

More quotes
  1. Stock Market
  2. Equities
  3. A048410 Stock